References
- Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290–293.
- Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol 2012;87:1038–1045.
- Druker BJ, Guilhot F, O’Brien SG, et al.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.
- Mascarenhas CC, Ferreira da Cunha A, Brugnerotto AF, et al. Identification of target genes using gene expression profile of granulocytes from patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma 2014;55:1861–1869.
- Kundu J, Wahab SMR, Kundu JK, et al. TOB1 induces apoptosis and inhibits proliferation, migration and invasion of gastric cancer cells by activating SMAD4 and inhibiting B-catenin signaling. Int J Oncol 2012;41:839–848.
- Athar M, Elmets CA, Kopelovich L. Pharmacological activation of p53 in cancer cells. Curr Pharm Des 2011;17:631–639.
- Grunwald M, Levis MJ. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol 2013;97:683–694.
- Leung AYH, Man CH, Kwong YL. FLT3 inhibition: a moving and evolving target in acute myeloid leukemia. Leukemia 2013;27:260–268.
- Cortes JE, Kantarjian H, Sha NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemia. N Engl J Med 2012;367:2075–2088.
- Smith CC, Lasater EA, Zhu X, et al. Activity of ponatinib against clinically relevant AC220 resistant kinase domain mutants of FLT3-ITD. Blood 2013;121:3165–3171.
- US Food and Drug Administration. Drug approvals and databases. Approved drugs. Ponatinib. Available from: www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm332368.htm
- ASH/FDA drug update. Available from: www.fda.gov/Drugs/DrugSafety/ucm373040.htm